Navigation Links
3SBio Inc. Announces Second Quarter 2008 Results
Date:8/12/2008

ompany and shareholder value.

Phase III Program Updates

High-dosage EPIAO

We have completed the full analysis of the Phase III trial to evaluate the safety and efficacy of a weekly subcutaneous injection of 36,000 IU EPIAO in oncology patients compared with a regimen of three times per week administration of 10,000 IU EPIAO. The results show that 70% of patients on high-dose EPIAO injections had Hemoglobin improvement of 1-2 mg/dl from baseline, similar to those on three times per week dosing of 10,000 IU EPIAO. More importantly, the weekly administration of 36,000 IU EPIAO demonstrated equivalent safety and tolerability profile as a three times per week 10,000 IU EPIAO. We remain on track to file with the SFDA in the third quarter of 2008. Pending approval by the SFDA, the once-weekly EPIAO will improve compliance for both existing and new patients as a result of greater convenience given the reduction in the number of injections required.

NuLeusin

Preliminary results from the analysis of the Phase III clinical trial data for NuLeusin (our second generation IL-2), completed in the first quarter 2008, demonstrated 11% partial response, with one patient registering a complete response. We are on track to file application for approval during the second half of 2008. Upon approval by the SFDA, we believe NuLeusin could be the first product of its kind for the treatment of late stage renal carcinoma available in China, and would provide an important treatment for late stage renal cancer patients who have exhausted other treatment options.

TPIAO for ITP

We have achieved our enrollment goal for the Phase III trial for TPIAO for the treatment of idiopathic thrombocytopenic purpura (ITP). We remain on track to file the application for approval with the SFDA in the fourth quarter of 2008.

TPIAO Phase IV Studies

To maximize the commercial potential and to ensure the continued long term growth of TPIAO, we initiate
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
8. 3SBio Inc. Announces Change to the Board of Directors
9. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015 YourEncore, an ... life sciences, consumer products and food sciences industries ... the Alliance for Clinical Research Excellence and Safety ... for conducting clinical research, have partnered to speed ... , YourEncore brings to ACRES experts with ...
(Date:4/20/2015)... MENLO PARK, Calif. , April ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical ... therapies in new orphan drug indications, today announced ... Meeting of the American Association for Cancer Research ... its lead product candidate VAL-083 (dianhydrogalactitol) ...
(Date:4/20/2015)... , April 20, 2015 ... for healing bone injuries. The orthobiologics market is a ... for its stakeholders. The global orthobiologics market report defines ... of revenue. The global orthobiologics market was valued at ... $7,900.2 million by 2019, at a CAGR of 6.7% ...
(Date:4/20/2015)... 20, 2015 PointCross Life Sciences today announced ... an integrated Big Data and globally accessible environment for ... the context of clinical trials and nonclinical studies. This ... drug candidates, stratified patient selection and ex post ... Highlighting the timing of this partnership, ...
Breaking Biology Technology:YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2
... TUALATIN, Ore. , Jan. 26 Waytronx, ... to the acquisition, development, and commercialization of new, innovative ... with British-based Ingenion Design Ltd. ("Ingenion") to develop and ... (GasPT2). , The GasPT2, designed by GL Industrial Services ...
... SHANGHAI , Jan. 26 /PRNewswire-Asia/ ... Company in China , announced,that a French delegation led ... January 22, 2010 . M.Raffarin, currently President,of Foundation Prospective ... Mr. Erwan Davoux of the foundation, and Dr. ...
... , , STOCKHOLM ... - part of,the Karolinska Development portfolio - announced today ... to continue its clinical,development program. Based on cardio-protective effects, ... new therapy for treating acute,coronary syndrome (ACS) and reperfusion ...
Cached Biology Technology:Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 2Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 3Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 4Former French Prime Minister Jean-Pierre Raffarin Visits Sundia 2Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy 2
(Date:4/1/2015)... 1, 2015   Medisafe ™, the leading global ... iOS and Android smartphones and ... into the platform to allow patients to track and ... first time, patients will be able to visualize in ... important biometrics, such as glucose levels and blood pressure. ...
(Date:3/31/2015)... , March 31, 2015   Guidepoint , ... launch of the Post-Surgical Pain Management TRACKER, part of ... tracking usage trends in the medical device and therapeutics ... to data including treatment volumes, market share, and adoption ... pain associated with joint surgery. The Post-Surgical ...
(Date:3/26/2015)... , March 26, 2015 The ... social, recreation and athletic club, today announced it has ... allow freedom of movement for members and staff, while ... a comprehensive process, we selected FST,s IMID Access system ... convenience for our members and staff, in addition to ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... vulnerable to their environment during embryonic development than females, ... University of Glasgow in the UK. Until now, the ... conditions during the embryonic stage in birds have received ... in Springers journal, Behavioral Ecology and Sociobiology. In ...
... of PocketCop Software, WALL, N.J., May 6 ... leader in finger-based biometric,identification and wireless public safety ... latest mobile data solution for BlackBerry(R),smartphones at the ... be held May 7-9 at the Gaylord Opryland ...
... brand now includes hi-tech gun and storage chest, ... BMRX), today announced that it has added two new ... which are,immediately available at retailers and online specialty sites., ... products as we grow our,smartTOUCH product line of consumer ...
Cached Biology News:Seagulls: Are males the weaker sex? 2BIO-key(R) Showcasing Public Safety Solutions for BlackBerry Smartphones at 2008 LEIM Conference 2BIO-key(R) Showcasing Public Safety Solutions for BlackBerry Smartphones at 2008 LEIM Conference 3bioMETRX, Inc. Introduces New Products 2
... serine/threonine phosphatase isolated from human red blood ... of 60kDa (A) and 36kDa (C) subunits. ... a-subunit of phosphorylase kinase. With its 3638kDa ... and may play a regulatory role in ...
... ATP Monitoring Kit measures adenosine ... sensitivity and a dynamic range. ... the assay measures ATP in ... over a concentration range of ...
... refrigerated cold traps offers a choice of ... solvents or high volatility solvents. Ideal to ... evaporators. Also used for maintaining vapor-free gas ... in electron microscopes. Can be used as ...
96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
Biology Products: